Acute Myeloid Leukemia: The Death Process Explained

Most people with acute myeloid leukemia (AML) who die from the disease do so because of infection, uncontrolled bleeding, or organ failure, not because of a single dramatic event. A landmark study of over 300 adults with acute leukemia found that infection, alone or combined with other factors, was the leading cause of death in roughly three out of four cases, followed by hemorrhage and organ failure.¹ These processes often overlap and reinforce one another, making the final trajectory a cascade rather than a clean sequence. Understanding how that cascade unfolds can help patients, families, and caregivers make sense of what is happening and why.

How AML Dismantles Normal Blood Production

At its core, AML kills by hijacking the bone marrow. Leukemic blast cells crowd out the normal stem cells that produce red blood cells, white blood cells, and platelets. But the damage goes beyond simply taking up space. Leukemia blasts release tiny packets called exosomes that suppress the function of healthy blood-forming cells and reprogram the bone marrow environment to favor leukemia growth instead of normal blood production.² The leukemia also releases signaling molecules like IL-6 that specifically block red blood cell development, worsening anemia.³

The result is a triple deficit: too few red blood cells (causing fatigue and oxygen deprivation), too few functional white blood cells (leaving the body defenseless against infection), and too few working platelets (making bleeding hard to stop). Each of these deficits can be life-threatening on its own. Together, they create conditions where minor infections become fatal, small bleeds become catastrophic, and organs begin to starve for oxygen. Everything that follows in the dying process stems from this fundamental collapse of normal blood production.

Infection and Sepsis

Infection is the single biggest killer in AML, and for a straightforward reason: the disease and its treatment both destroy the immune system’s front-line defenders. When the white blood cell count drops to dangerously low levels after chemotherapy, patients enter a state called neutropenia, where the body has almost no ability to fight off bacteria or fungi. In a study tracking nearly 300 chemotherapy cycles in 84 AML patients, neutropenic fever occurred in 97% of those cycles. Severe sepsis developed in about 13% of episodes, and roughly one in nine patients died from it.⁴

The infections themselves are often opportunistic, caused by organisms that would pose little threat to someone with a functioning immune system. Bacteria that normally live harmlessly in the gut can enter the bloodstream through microscopic breaks in the intestinal lining, which chemotherapy damages. Fungi like Aspergillus can colonize the lungs. In many cases, the source of infection is never identified because the immune system is too suppressed to mount the inflammatory response that would normally produce localizable symptoms like pus or swelling. Fever may be the only sign, and by the time blood cultures come back positive, the infection may already be overwhelming.

What makes sepsis lethal in AML is the body’s inability to mount a proportional defense. In a healthy person, the immune system can usually contain a bloodstream infection. In someone with AML, the combination of absent neutrophils, damaged mucosal barriers, and often indwelling catheters creates a perfect storm. When the immune system does attempt a response, it can swing into an exaggerated inflammatory cascade. Inflammatory signaling molecules like IL-6, IL-8, and TNF-α surge to abnormally high levels, especially in patients who develop severe infections.⁵ This cytokine storm can itself cause widespread tissue damage, organ dysfunction, and multi-organ failure, even if the original infection is controlled with antibiotics.

Hemorrhage and Uncontrolled Bleeding

Bleeding is the second most common cause of death in AML. Autopsy studies have found that fatal hemorrhages, most often in the brain or the gastrointestinal tract, account for roughly 30% of deaths.⁶ The bone marrow failure caused by AML produces not only too few platelets but dysfunctional ones, compounding the bleeding risk far beyond what the numbers alone would predict.⁷

Intracranial hemorrhage is particularly feared because it can happen suddenly, sometimes as the very first sign of the disease, and it is often fatal before treatment can begin. Even relatively minor trauma can trigger dangerous internal bleeding in someone with severely depleted platelets. Platelet transfusions help, but in advanced or refractory disease, the benefit becomes increasingly short-lived as the body rapidly consumes or destroys transfused platelets.

The Special Case of Acute Promyelocytic Leukemia

One AML subtype, acute promyelocytic leukemia (APL), carries an especially high early death risk from bleeding because of a severe clotting disorder. APL cells produce tissue factor, a protein that triggers the clotting cascade inappropriately. As APL cells die, either spontaneously or from treatment, they release bursts of this clotting activator, which paradoxically causes both excessive clotting and bleeding simultaneously.⁸ The clotting system becomes so disordered that it exhausts the body’s supply of clotting factors, a condition called disseminated intravascular coagulation. This leaves patients at catastrophic risk for brain bleeds and other fatal hemorrhages, particularly in the first days after diagnosis. APL is actually one of the most curable AML subtypes if treatment starts quickly, but many patients die before treatment has time to work.

Leukostasis and Acute Vascular Crises

When the blast count in the bloodstream climbs extremely high, a dangerous condition called leukostasis can develop. Unlike normal white blood cells, leukemic blasts are large, sticky, and rigid. In enormous numbers, they physically clog small blood vessels, particularly in the lungs and brain. This causes respiratory distress, neurological symptoms like confusion or stroke-like episodes, and organ dysfunction from tissue oxygen starvation.⁹

Leukostasis is a medical emergency. Patients can deteriorate within hours as the oxygen supply to vital organs is choked off. Treatment involves rapidly reducing the blast count through chemotherapy or a procedure called leukapheresis, which mechanically filters blast cells from the blood. Even with treatment, leukostasis carries a high early mortality rate. For families, this is one of the most frightening aspects of AML because the decline can be rapid and dramatic, going from seemingly stable to critically ill in a matter of hours.

Organ Infiltration

AML is not strictly a blood and bone marrow disease. Leukemic blasts can physically invade organs throughout the body. Autopsy findings have revealed dense leukemic infiltration of the heart, lungs, liver, kidneys, and thyroid, even in patients whose blood counts did not suggest an overwhelming disease burden.¹⁰ In the lungs, blasts accumulate around blood vessels and airways. In the liver, they pack into the portal tracts and cause bile to back up. In the kidneys, they cluster in the cortex where blood filtration occurs.

A single-center study tracking extramedullary involvement over ten years found that the most common sites outside the marrow were the skin, central nervous system, pleura, and lymph nodes.¹¹ Skin involvement, affecting about two-thirds of those with extramedullary disease, often appears as firm, painless nodules. Central nervous system involvement can cause headaches, vision changes, or confusion. The clinical significance of organ infiltration is that it can contribute to organ failure even when chemotherapy is clearing blasts from the blood and marrow. Organs that have been quietly infiltrated for weeks may suddenly declare themselves as the leukemia burden shifts.

Tumor Lysis Syndrome and Metabolic Collapse

Paradoxically, one of the most dangerous moments in AML is when treatment starts working. When chemotherapy kills a large number of blast cells quickly, those dying cells dump their internal contents into the bloodstream all at once. Potassium, phosphorus, and uric acid spike to dangerous levels. The kidneys, already stressed, struggle to clear this toxic load. Among patients who developed tumor lysis syndrome in one intensive care study, about 80% went into acute kidney injury and over half required dialysis.¹²

The metabolic fallout from tumor lysis can be fatal on its own. High potassium levels cause dangerous heart rhythm abnormalities. High phosphorus binds to calcium, driving calcium levels down and causing seizures and muscle spasms. Uric acid crystals can clog the kidney’s tiny filtration tubules, shutting down urine production entirely. Clinicians give preventive medications and fluids before starting chemotherapy to reduce this risk, but in patients with very high blast counts, tumor lysis can outpace the body’s ability to compensate.

Clonal Evolution and Treatment Resistance

Even when the initial treatment achieves remission, AML has a formidable ability to come back. This happens because AML is not a single uniform population of cancer cells. It is a diverse ecosystem of genetically distinct subpopulations, each carrying different combinations of mutations, competing and cooperating with each other.¹³ Chemotherapy may eliminate the dominant population, but a minor subclone carrying a resistance-conferring mutation can survive and expand to become the new dominant leukemia.

Research tracking the molecular genetics of AML patients from diagnosis through relapse has shown that the dominant clone at relapse often differs from the one at diagnosis, with new mutations driving growth and new resistance profiles.¹⁴ This evolutionary adaptability is a central reason why AML relapse is so difficult to treat. The relapsed disease is, in a real sense, a different leukemia than the one originally treated. Clonal evolution is recognized as a driving force behind both drug resistance and disease relapse.¹⁵

For the patient, this means that each successive line of treatment tends to work less well, and the windows of remission tend to get shorter. The disease eventually reaches a point where it no longer responds to available therapies, and the bone marrow failure, infection, and bleeding pathways described above reassert themselves without meaningful opposition.

Treatment-Related Mortality

A reality often underappreciated outside oncology is that AML treatment itself carries a significant death risk. Intensive chemotherapy regimens and bone marrow transplants are among the most dangerous treatments in medicine. In pediatric AML trials, the rate of early death or treatment-related mortality on one protocol was about 18%, falling to roughly 8% on a successor trial with improved supportive care.¹⁶ These are children, who generally tolerate treatment better than older adults.

For allogeneic stem cell transplant, which is often the best chance for a cure in high-risk AML, non-relapse mortality was about 26% at two years and 34% at ten years in a large registry analysis. That means roughly one in four transplant patients died from complications of the transplant itself, not from leukemia coming back.¹⁷ Graft-versus-host disease, where the donated immune cells attack the patient’s own organs, is a major contributor. So are infections during the prolonged period of immune suppression that follows transplant, and organ toxicity from the conditioning chemotherapy or radiation used to prepare the body for the new marrow.

This puts patients and families in a genuinely difficult position. Forgoing intensive treatment means the leukemia is almost certain to be fatal. Pursuing it means accepting a treatment that could itself kill you. For older adults with other health problems, the calculus is especially stark, and many oncologists will discuss less intensive approaches or palliative-focused care as a legitimate alternative.

How the Dying Process Unfolds in Practice

In clinical reality, AML deaths rarely have a single clean cause. A common trajectory involves overlapping crises. A patient with refractory disease may develop pneumonia because their white count is near zero. The pneumonia triggers sepsis. The sepsis activates a cytokine storm that damages already-stressed organs. Simultaneously, platelet counts plummet, and the patient develops gastrointestinal bleeding that cannot be controlled. The kidneys, taxed by the combination of low blood pressure from sepsis and toxic metabolic byproducts, stop producing urine. Consciousness dims as the brain loses adequate blood flow and oxygenation.

Delirium and confusion are common in the final phase. These can result from infection, metabolic derangements, medications, bleeding into the brain, or some combination.¹⁸ For families at the bedside, the shift from lucidity to confusion can be one of the most distressing changes, because it often signals that the body’s compensatory mechanisms are failing across multiple systems simultaneously.

A registry analysis of over 3,000 deaths in children, adolescents, and young adults with AML found that about 71% of deaths were attributed directly to AML, while roughly 18% were from second cancers and about 11% from non-cancer causes. Among the non-cancer causes, infectious diseases were the most common, followed by cardiovascular disease and sepsis.¹⁹ Among patients who survived beyond five years, the proportion of deaths from AML itself dropped below half, while non-cancer causes, including heart disease and infection, rose substantially. Survivorship does not end the risk; it changes its character.

Why Timing Hospice and Palliative Care Is So Difficult

Unlike many solid tumors, where the trajectory from diagnosis to death is somewhat predictable, AML’s course can shift abruptly. A patient can be in remission one month and critically ill the next. Conversely, patients who appear to be dying sometimes respond to a new treatment and improve. This unpredictable illness trajectory complicates the timing of hospice referral and can delay access to comfort-focused care, leading to more hospitalizations and invasive procedures near the end of life.²⁰

There is growing evidence that integrating palliative care earlier, alongside active treatment rather than only after treatment fails, improves quality of life and psychological well-being. A randomized trial of inpatient palliative care for AML patients found that those who received it developed better coping strategies, and these improvements in coping accounted for the majority of the palliative care intervention’s positive effect on quality of life and reduction in depression symptoms.²¹ Palliative care in this context does not mean giving up. It means having parallel conversations about both fighting the disease and preparing for the possibility that the fight does not succeed.

For families trying to understand what is happening to a loved one, the hardest part is often the speed and the uncertainty. AML can transform a seemingly healthy person into a critically ill patient in days. The dying process, when it comes, often involves multiple overlapping crises that feel chaotic from the outside even when the medical team understands the underlying mechanisms. Knowing that infection, bleeding, and organ failure are the primary pathways, and that they tend to accelerate each other, can at least provide a framework for understanding what the body is going through and why certain interventions are or are not being pursued.

Long-Term Survivors and Shifting Causes of Death

Not everyone who dies after an AML diagnosis dies from the leukemia itself, especially among those who achieve long-term survival. In the registry study of younger AML patients, those who lived beyond five years saw a pronounced shift in what ultimately killed them. AML accounted for about 45% of deaths in this late group, while non-cancer causes, led by cardiovascular disease and infections, accounted for roughly a third.¹⁹ Second cancers, often related to the chemotherapy or radiation used to treat the original leukemia, were responsible for about one in five late deaths.

This pattern reflects the lasting damage that AML treatment inflicts on the body. Chemotherapy agents can weaken the heart muscle. Radiation and alkylating agents increase the risk of developing an entirely different cancer years later. Chronic graft-versus-host disease after transplant can cause organ scarring that accumulates over time. Survivors often live with a heightened baseline risk for infections, cardiovascular events, and second malignancies that persists for decades. The death process for a long-term AML survivor may look nothing like AML at all; it may look like heart failure, a new solid tumor, or a severe lung infection in someone whose immune system never fully recovered.